/index.php?option=com_iwpfile&file=/dir_01/he2002_2668.pdf


/index.php?option=com_iwpfile&file=/dir_01/he2002_2670.pdf


on

October 18, 2002

For Immediate Release

The Department of Health and Human Services (HHS) welcomes the passage of legislation that would provide the Food and Drug Administration's (FDA) device review program with the same type of successful funding system that has been used over the last decade for the agency's drug and biologics reviews. Under this system, device manufacturers would pay fees to FDA for the review of their new product applications, and these funds would, in turn be used specifically to enhance FDA's devices review program.



October 18, 2002

For Immediate Release

The Department of Health and Human Services (HHS) today announced the Medicare premium, deductible and coinsurance amounts to be paid by Medicare beneficiaries in 2003.



ne

National Institute of Health

News Release

For Immediate Release

October 21, 2002

The National Center for Complementary and Alternative Medicine (NCCAM) and 16 Federal co-sponsors announce the launch of an Institute of Medicine (IOM) study of the scientific and policy implications of the use of complementary and alternative medicine (CAM) by the American public. The $1 million, nearly 2-year study, will be conducted by the IOM, a component of the National Academies.



ds

October 9, 2002

The Honorable Max Baucus

Chairman

Committee on Finance

United States Senate

Washington, D.C. 20510

The Honorable Charles Grassley

Ranking Member

Committee on Finance

United States Senate

Washington, D.C. 20510

The Honorable W.J. (Billy) Tauzin

Chairman

Committee on Energy and Commerce

U.S. House of Representatives

Washington, D.C. 20515

The Honorable John D. Dingell

Ranking Member

Committee on Energy and Commerce





/index.php?option=com_iwpfile&file=/dir_01/he2002_2661.pdf


/index.php?option=com_iwpfile&file=/dir_01/he2002_2660.pdf


/index.php?option=com_iwpfile&file=/dir_01/he2002_2659.pdf


Pages

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.